Wang Yi-Hui, Song Zhen, Hu Xin-Yuan, Wang Huai-Song
Key Laboratory of Drug Quality Control and Pharmacovigilance (Ministry of Education), China Pharmaceutical University, Nanjing, 210009, China; Department of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing, 210009, China.
Key Laboratory of Drug Quality Control and Pharmacovigilance (Ministry of Education), China Pharmaceutical University, Nanjing, 210009, China; Department of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing, 210009, China.
Talanta. 2021 Jun 1;228:122220. doi: 10.1016/j.talanta.2021.122220. Epub 2021 Feb 19.
Tumor is a kind of abnormal organism generated by the proliferation and differentiation of cells in the body under the action of various initiating and promoting factors, which seriously threatens human life and health. Tumorigenesis is a gradual process that involves multistage reactions and the accumulation of mutations. Gene mutation usually occurs during tumorigenesis, and can be used for tumor diagnosis. Early diagnosis is the most effective way to improve the cure rate and reduce the mortality rate. Among the peripheral blood circulating tumor DNA (ctDNA), gene mutation in keeping with tumor cells can be detected, which can potentially replace tumor tissue section for early diagnosis. It has been considered as a liquid biopsy marker with good clinical application prospect. However, the high fragmentation and low concentration of ctDNA in blood result in the difficulty of tumor stage determination. Therefore, high sensitive and specific mutation detection methods have been developed to detect trace mutant ctDNA. At present, the approaches include digital PCR (dPCR), Bead, Emulsion, Amplification and Magnetic (BEAMing), Next Generation Sequencing (NGS), Amplification Refractory Mutation System (ARMS), etc. In this paper, the principle, characteristics, latest progress and application prospects of these methods are reviewed, which will facilitate researchers to choose appropriate ctDNA detection approaches.
肿瘤是机体在各种启动和促进因素作用下,体内细胞增殖分化形成的异常机体,严重威胁人类生命健康。肿瘤发生是一个涉及多阶段反应和突变积累的渐进过程。基因突变通常发生在肿瘤发生过程中,可用于肿瘤诊断。早期诊断是提高治愈率和降低死亡率的最有效方法。在外周血循环肿瘤DNA(ctDNA)中,可以检测到与肿瘤细胞一致的基因突变,其有可能替代肿瘤组织切片用于早期诊断。它被认为是一种具有良好临床应用前景的液体活检标志物。然而,血液中ctDNA的高度碎片化和低浓度导致肿瘤分期判定困难。因此,已开发出高灵敏度和特异性的突变检测方法来检测痕量突变ctDNA。目前,这些方法包括数字PCR(dPCR)、磁珠、乳液、扩增和磁性技术(BEAMing)、新一代测序(NGS)、扩增阻滞突变系统(ARMS)等。本文对这些方法的原理、特点、最新进展及应用前景进行综述,有助于研究人员选择合适的ctDNA检测方法。